

1 Risk of adverse pregnancy outcomes and impact of statin use in 2 pregnant women with familial hypercholesterolemia

3 Karianne Svendsen^{1,2,3} kasv@kreftregisteret.no

4 Jacob Juel Christensen² j.j.christensen@medisin.uio.no

5 Jannicke Igland^{4,5} Jannicke.Igland@uib.no

6 Henriette Walaas Krogh^{6,2} henriette.walaas.krogh@helsedir.no

7 Liv J. Mundal¹ lmundal@yahoo.no

8 David R. Jacobs Jr.⁷ jacob004@umn.edu

9 Martin P. Bogsrud⁸ mabogs@ous-hf.no

10 Kirsten B. Holven^{2,9} k.b.holven@medisin.uio.no

11 Kjetil Retterstøl^{1,2} kjetil.retterstol@medisin.uio.no

12 ¹Lipid Clinic, Oslo University Hospital, Oslo, Norway.

13 ²Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo,
14 Norway.

15 ³Cancer Registry of Norway, Norwegian Institute of Public Health, 0379 Oslo, Norway.

16 ⁴Department of Global Public Health and Primary Care, University of Bergen, Bergen,
17 Norway; Department of Health and Social Science, Centre for Evidence-Based Practice,
18 Western Norway

⁵Department of Health and Caring Sciences, Western Norway University of Applied Sciences,
Bergen, Norway

⁶Department of Non-Communicable Diseases, Division of Prevention and Public Health,
Norwegian Directorate of Health, Oslo, Norway.

⁷University of Minnesota, Minneapolis, Minnesota, USA

⁸Unit for Cardiac and Cardiovascular Genetics, Oslo University Hospital, Oslo, Norway.

⁹Norwegian National Advisory Unit on Familial Hypercholesterolemia, Oslo University
Hospital, Oslo, Norway.

Short title: Adverse pregnancy outcomes in women with familial hypercholesterolemia

Corresponding author: Karianne Svendsen, kasv@kreftregisteret.no, Oslo University
Hospital, Department for endocrinology, morbid obesity and preventive medicine, postal
box 4959 Nydalen, Norway.

Key words

Familial hypercholesterolemia; adverse pregnancy outcomes; statins; low birthweight,
premature births; preeclampsia; diabetes; bleedings; c-section; malformations

1 Abstract

2 **Background and aims:** Sparse data exist on the possible risk of adverse pregnancy

3 outcomes in women with familial hypercholesterolemia (FH). We investigated

4 associations between having a FH diagnosis and adverse pregnancy outcomes, and

5 between statin exposure in pregnancy and adverse pregnancy outcomes among

6 women with FH.

7 **Methods:** This registry-based study included 3869 pregnancies among 1869 women

8 with FH and 68225 pregnancies among 33661 women from the general population.

9 Data on adverse pregnancy outcomes were obtained from the Medical Birth Registry of

10 Norway with data from 1967-2018. Data on pharmacy-dispensed statins were obtained from

11 the Norwegian prescription database (2004-2018) in 1051 women with FH. Associations

12 were presented as odds ratio (OR) with 95% CI from logistic regression adjusted for mother's

13 age, parity, and offspring's birth year.

14 **Results:** Women with FH had a higher risk of preeclampsia (OR 1.21 [1.00-1.46]), but lower

15 risk for gestational diabetes (OR 0.58 [0.36-0.92]) and intrapartum hemorrhage during

16 delivery (OR 0.81 [0.71-0.92]) compared to controls. No excess risk of adverse pregnancy

17 outcome in offspring was observed for FH vs controls. Women with FH using statins in

18 pregnancy (n=260) had a higher risk of having offspring with low (<2500 g) birth weight (OR

19 2.20 [1.11, 4.49]) compared to non-exposed women with FH (n=791).

20

- 1 **Conclusions:** Women with FH had lower risk of gestational diabetes and intrapartum
- 2 hemorrhage during delivery and non-significantly higher risk of preeclampsia compared to
- 3 controls. No difference in adverse pregnancy outcomes in the offspring was observed. Statin
- 4 exposure in pregnancy was associated with a higher risk of having offspring with low birth
- 5 weight among women with FH, and this association warrants further investigations.
- 6

1 Introduction

2 Individuals with familial hypercholesterolemia (FH) have an inherited condition that reduces
3 the capacity to clear LDL-cholesterol (LDL-C) particles from the circulation ¹, leading to
4 accelerated atherosclerosis, and excess risk of premature coronary heart disease (CHD) ^{2, 3}.
5 There is a physiological increase in blood lipids during pregnancy, and statins are
6 contraindicated during pregnancy and lactation ⁴. Thus, women with FH may experience
7 significantly heightened levels of LDL-C without the option of statin treatment ^{5, 6}. The
8 potential atherogenic consequences of this dual increase in LDL-C in women with FH are
9 incompletely understood ⁷.

10 Although hypercholesterolemia is not normally mentioned as a risk factor ⁴, it has
11 been linked to higher risk of preeclampsia ^{8, 9}, and blood lipid dysregulation is again strongly
12 associated with gestational diabetes ⁷. Since diet and lifestyle are significant predictors of
13 both hypercholesterolemia, preeclampsia and gestational diabetes ^{10, 11}, genetically verified
14 FH can serve as a model for studying the impact of hypercholesterolemia in isolation. Using
15 Norwegian health registry linkage in a sub-sample of the present FH population, it was
16 reported that offspring from mothers with FH who carried to full-term did not have a higher
17 risk of selected adverse pregnancy outcomes ¹². However, diagnostics of these conditions
18 have improved over time, and it is unknown whether the risk of preeclampsia, gestational
19 diabetes and gestational hypertension differ between women with and without genetically
20 verified FH today.

21 Due to the limited information on safety of statin use during pregnancy and lactation,
22 a precautionary and individualized approach comparing risks and benefits of statin use in
23 pregnancy and during lactation is recommended ^{4, 13, 14}. Because many women may not

1 realize they are pregnant until a few weeks after conception, some women might
 2 unknowingly have exposed their offspring to statins. This is mostly relevant in women with
 3 FH who is recommended to start lifelong statin therapy in adolescence ^{15, 16}. About 30% of a
 4 subsample of Norwegian women with FH have used statins in their early pregnancy ¹⁷. This
 5 represents a challenge for statin treated women who worry about potential adverse effects
 6 of statin use on their offspring ¹⁷⁻¹⁹. Although some studies have shown no teratogenic effect
 7 of maternal statin use ^{18, 20}, other studies of women from the general population have
 8 suggested that statin use may be associated with premature birth and low birth weight ^{21, 22}.
 9 Hence, in terms of the association between FH and adverse pregnancy outcomes and statin
 10 use in pregnancy, there is still little robust data to ease the worry.

11 The aim of this study was to compare women with FH and controls on terms of risk
 12 of adverse pregnancy outcomes for mothers and offspring, and to investigate associations
 13 between statin exposure in pregnancy and adverse outcomes among women with FH.

14

1 Methods

2 Study design and variables

3

4 The study originates from a registry-based matched cohort-study of individuals with a
5 genetically verified FH diagnosis from the Unit for Cardiac and Cardiovascular Genetics
6 (UCCG) database at Oslo University Hospital²³. The controls (1:20) were drawn from the
7 general Norwegian population matched on sex and year of birth²⁴. Women from these
8 cohorts with one or more pregnancies were included in the present study.

9 Data on pregnancy characteristics and adverse pregnancy outcomes during 1967-
10 2018 were obtained from The Medical Birth Registry (MBRN)²⁵. This registry contains data
11 on women's health during pregnancy, childbirth and in the maternity period, and children's
12 health from birth and up to one year of age²⁵. In the present study, for all available
13 pregnancies, we obtained from the MBRN information on mother's birth year, age at birth,
14 height and weight before- and at end of pregnancy (data available from 2007 and only from
15 about 40% of the hospitals), smoking habits (data available from 1999 but with <50% of the
16 data missing), mother's health prior to pregnancy (including occurrence of diabetes mellitus
17 [type 1, 2 or unspecified] and chronic hypertension), previous spontaneous abortions
18 (before week 12 and 12-23), and last menstruation period. Data on pregnancy characteristics
19 such as date of birth and age of mothers, body mass index (BMI) at start and end of
20 pregnancy (BMI information was only available from 2007 and from about 40% of all
21 institutions), in vitro fertilization (IVF), preeclampsia, gestational hypertension, gestational
22 diabetes, intrapartum hemorrhage (defined as \geq large bleedings 500 ml during delivery) and
23 delivery methods were also included. Furthermore, the offspring's date of birth, birth
24 weight, gestational length (days and weeks), preterm births (defined as births prior to

1 gestational week 37), mean birthweight and different categories of birth weight (low birth
2 weight (<2500 grams), high birth weight (>4500 grams), birthweight <10th and 25th
3 percentiles), Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) scores (tests of
4 newborns immediately after delivery), complications during birth, occurrence of various
5 malformations combined to one group “any malformation”, congenital heart defects,
6 stillbirths and neonatal deaths.

7 The Norwegian Prescription database contains information on pharmacy-dispensed
8 prescriptions ²⁶. We obtained data on dispensing date, year, number of packages, number of
9 daily defined doses, category, category numbers, reimbursement code, package size, drug
10 strength and daily defined doses of the Anatomical Therapeutic Chemical (ATC) codes C10AA
11 and C10BA (statins and statins in combination with ezetimibe) during 2004-2018. Statin use
12 before, during and after pregnancy was estimated by linking information on statin use with
13 data from the MBRN on last menstruation period, birth date and gestational length. Statin
14 use during pregnancy was defined as filling at least one prescription for statins either during
15 pregnancy or before conception if the prescription package duration would last into
16 pregnancy, assuming one tablet per day (here termed overlap).

1 Study population

2 There were 4112 pregnancies among 1926 women with FH and 72727 pregnancies among
3 34389 controls. The exclusion criteria were pregnancies with missing gestational length or
4 gestational length <22 weeks, as well as those with missing birth weight and plural
5 pregnancies. The final dataset available for analysis comprised 3869 pregnancies among
6 1869 women with FH, and 68225 pregnancies among 33661 women in the control group
7 (Figure 1).

8 In the analysis of statin exposure, only those pregnancies with birth year between
9 1.1.2005-31.12.2018 were included to have complete coverage on prescription data up to
10 one year prior to birth. In total, 1051 pregnancies among women with FH were available for
11 these analyses.

12

13 Statistical analysis

14 Pregnancy characteristics were presented with mean and standard deviation (SD) or
15 frequency and percentages (%). Associations between FH status and adverse pregnancy
16 outcomes (all binary variables), and statin exposure and adverse pregnancy outcomes were
17 analyzed with logistic regression and presented as odds ratio (OR) with 95% confidence
18 intervals (95% CI). Confidence intervals were estimated using clustered robust standard
19 errors to take into account dependencies between pregnancies for women with more than
20 one pregnancy. CI overlapping 1 indicated non-significance, corresponding to a significance
21 level equal to 5%. Data were analyzed unadjusted and adjusted for the mothers' age at
22 pregnancy, parity and the children's birth year (in 5-year categories), and results from the
23 adjusted models were reported as the main results. Using the same method as described

1 above, we did a sensitivity analysis of the interaction between adverse birth effects and
2 known FH status.

3 Data management and analyses were performed in STATA version 18 (StataCorp.
4 2023. Stata Statistical Software: Release 18. College Station, TX: StataCorp LLC.) and R Studio
5 version 2023.03.1 (Posit PBC, Boston, MA, USA).

6 Consent

7
8 The implementation of the study complies with the Declaration of Helsinki. Consent was
9 required to be included in the UCCG database, and no additional consent was needed to be
10 included in the present study. However, individuals in the FH cohort had the opportunity to
11 withdraw from the study until May 1, 2014. Consent was not needed to be included in the
12 control cohort.

1 Results

2 Pregnancy-related characteristics

3 The age at genetically confirmed FH diagnosis was mean 38.9 (14.9) years. At time of
4 delivery, women with FH were on average 27.8 (5.4) years and controls 27.9 (5.4) years.
5 Parity, reported BMI at the start and end of pregnancy, number of smokers and previous
6 spontaneous abortions were similar among women with and without FH. In total 0.5%
7 (n = 21) of women with FH had chronic hypertension, and 0.1% (n = 5) diabetes mellitus
8 before pregnancy, whereas the corresponding percentages in controls were 0.3% (n = 238)
9 and 0.4% (n = 291) (Table 1). The proportion with in vitro fertilization was 0.8% (n = 30) in
10 women with FH and 1.1% (n = 749) in controls (p=0.06).

11 Adverse pregnancy outcomes

12 A higher proportion of women with FH (3.4% n = 133) than controls (2.9%, n = 1951) were
13 diagnosed with preeclampsia during pregnancy (OR 1.21 [95% CI 1.00-1.46]). Gestational
14 diabetes was observed in 0.6% (n = 22) of pregnancies in women with FH, and in 1% (n =
15 679) of pregnancies in controls (OR 0.58 [95% CI 0.36-0.92]). A lower proportion of women
16 with FH (8.5%, n = 328) experienced intrapartum hemorrhage during delivery compared to
17 controls (10.0 %, n = 6876) (OR 0.81 [95% CI 0.71-0.92]). The frequency of gestational
18 hypertension and cesarean deliveries (c-sections) were similar among cases and controls
19 (Figure 2).

20 Mean birth weight, proportion with low- and high birth weight, and preterm birth
21 were all similar in offspring from mothers with FH and controls. Similarly, there were no
22 differences in any malformations, stillbirths, or neonatal deaths between offspring of
23 women with and without FH (Table 1 and Figure 3).

1 APGAR scores were similar between FH and controls: APGAR 1 was 8.7 (SD 1.2) in
2 both FH and controls, and APGAR 5 was 9.3 (SD 0.9) in FH and 8.7 (SD 1.2) in controls.

3 Sensitivity analysis

4 FH was diagnosed prior to pregnancy in 27.6% (n=1067) of all pregnancies of which the
5 majority (n=867) were diagnosed in 2005 or earlier (the earliest available date for diagnosis
6 was 1992). For 34 women, FH was diagnosed during pregnancy.

7 When stratifying the analyses by pregnancies with births before or equal to 2005
8 (n = 2818 in FH and 50184 in controls) and after 2005 (n = 1051 in FH and 18040 in controls),
9 as a proxy for unknown versus known FH during pregnancy, the ORs for adverse pregnancy
10 outcomes were like those of the total study population. E.g., the ORs for preeclampsia were
11 1.24 (95% CI: 0.99-1.54) and 1.14 (95% CI: 0.80, 1.61) and the ORs for gestational diabetes
12 were 0.58 (95% CI: 0.24, 1.42) and 0.58 (95% CI: 0.34, 0.99) between cases and controls with
13 offspring born before and after 2005, respectively.

14

15

16

17

1 Statin use in pregnancy in women with FH

2 Of the 1051 pregnancies during 2005-18 among women with FH, 37.4% (n = 393) were
3 exposed to statins 6-12 months prior to conception, and 25% (n = 260) during pregnancy
4 (Table 2). The frequency of dispersion of statin prescriptions in all women with FH from one
5 year before conception to one year after birth is visualized in Figure 4.

6 Statin-exposed (n = 260) and non-exposed (n = 791) pregnancies in women with FH
7 had similar mean age at birth and mean BMI at end of pregnancy, whereas mean BMI at the
8 start of pregnancy was slightly higher in the statin-exposed group (24.9 [SD 0.4]) compared
9 to in the non-exposed group (23.9 [SD 0.3]). There was a similar number of smokers and less
10 than five women with diabetes prior to pregnancy in both groups (Table 3).

11 There was no difference in the risk of preeclampsia, gestational hypertension,
12 gestational diabetes, or intrapartum hemorrhage between pregnancies exposed- and not
13 exposed to statins. Low birth weight occurred more frequently in pregnancies exposed to
14 statins (OR 2.20 [95% CI: 1.11, 4.49]). There were similarly, although non-significant, higher
15 proportion of the statin exposed pregnancies that experienced preterm birth (OR 1.74 [95%
16 CI: 0.93, 3.24]) and proportion with birth weight below the 10th percentile (OR 1.33 [95% CI:
17 0.78, 2.20]).

18 Among the statin exposed pregnancies, 44% (n= 8) of the premature births had c-
19 section as delivery method, whereas the corresponding numbers in the non-exposed group
20 was 15% (n = 37). Thus, c-section was more common among the statin-exposed pregnancies
21 (OR was 1.55 [95% CI: 1.03, 2.31]). The results for subgroups of c-section were however
22 divergent: there was a non-significant higher OR for acute c-section (OR 1.25 [95%CI: 0.6,

2.5]), and non-significant lower odds for scheduled/planned c-section (0.7 [95%CI: 0.4, 1.6]) among the statin exposed pregnancies.

The number of cases was too low to investigate the risk of neonatal deaths, stillbirths and congenital heart defects in statin exposed versus non-exposed pregnancies among women with FH.

Statin use in controls

Statins were used in 16 pregnancies among controls, of whom less than five had a low birthweight offspring and/or delivered a pre-term baby. Due to the small sample size, no further statistical analysis of associations with statin exposure among controls was performed.

1 Discussion

2 With data on 3869 pregnancies among women with genetically verified FH, this is the largest
3 study to date on pregnancy outcomes in women with FH. FH was associated with lower risk
4 of gestational diabetes and intrapartum hemorrhage during birth and higher, non-
5 significantly risk of preeclampsia compared to controls. There was no excess risk for other
6 adverse pregnancy-related outcomes in either the mothers with FH, or their offspring. Statin
7 use during pregnancy was associated with a higher risk of having offspring with low birth
8 weight, as well as a (non-significantly) higher proportion of preterm births, compared to
9 non-exposed pregnancies.

10 Previous studies showing an association between hypercholesterolemia and
11 preeclampsia and gestational diabetes in general populations ^{8, 9, 27} may be limited by
12 reverse causality and confounding factors because hypercholesterolemia is strongly
13 associated with an unhealthy dietary pattern, age, physical inactivity, insulin resistance and
14 overweight and obesity – all well-known risk factors for preeclampsia ^{11, 28} and gestational
15 diabetes ^{10, 29}. The genetic predisposition that leads to FH allows us to study the role of LDL-
16 C in risk of adverse pregnancy outcomes less biased of reverse causality. Moreover, in the
17 current study, the common risk factor BMI at start and end of pregnancy were similar among
18 the FH and control populations, and there was a very low percentage with diabetes mellitus
19 before pregnancy in both groups. Furthermore, there was no significant interaction between
20 estimated known FH status and risk of any outcomes, ruling out possible detection bias as
21 women with FH may be more closely followed-up in the health-care system in general.

22 Nonetheless, (chronic) hypertension, the main risk factor for preeclampsia ²⁸ was
23 somewhat higher among women with FH (0.5%) compared to controls (0.3%), despite that

1 similar frequencies of hypertension (not limited to chronic) in the total FH population
2 compared to controls have previously been reported ³⁰.

3 In 2011 we reported that women with FH had no excess risk of gestational diabetes
4 during follow-up (1967-2006). ¹². However, diagnostics and registration of gestational
5 diabetes in Norway have improved after 2006, and the prevalence has significantly and
6 simultaneously increased annually according to Medical Birth Registry statistics ³¹. As an
7 example, between 2010 and 2016 the prevalence of gestational diabetes increased from
8 2.6% to 6% ³². Given that we in the present study report risk of gestational diabetes between
9 1967 and 2018, the association between FH and gestational diabetes may be
10 underestimated.

11 The observed 19% lower risk of intrapartum hemorrhage during delivery in the FH
12 population was somewhat surprising. The difference cannot be explained by some major risk
13 factors (multiple pregnancies, older age, high BMI, IVF, high birth weight babies, c-section,
14 preeclampsia) ³³ as the occurrence of these risk factors were similar among FH and controls.
15 In search of an explanation, we looked to the well-established association between high
16 levels of Lp(a) and lower risk of significant hemorrhage in general ^{34, 35}. This could be
17 relevant as high Lp(a) levels has been observed in the Norwegian FH cohort ³⁶⁻³⁸. However,
18 high Lp(a) is not a general trait in all individuals with genetically verified FH ^{39, 40}.

19 The observed borderline higher risk of preeclampsia in women with FH, extending
20 our previous non-significant finding in a smaller sample of the population group ¹², and the
21 novel findings of lower risk of gestational diabetes and intrapartum hemorrhage, may
22 therefore represent an argument that high LDL-C in itself is a player and not only a bystander
23 in the development of these pregnancy-related disorders.

1 Adverse outcomes in offspring

2 In line with our previous work ¹², and compared to a matched control group, we found that
3 women with genetically verified FH did not have a significantly higher risk of low birth
4 weight or preterm delivery adjusting for the mothers' age at pregnancy, parity and children's
5 birth year. The FH population did not have a higher risk of having infants with congenital (or
6 any) malformations compared to controls, although clear conclusions cannot be drawn due
7 to low number of cases.

8 We observed a 2.2 (95% CI: 1.11, 4.49) higher odds of low birth weight in offspring
9 from mothers with FH with statin prescriptions dispensed during pregnancy, compared to
10 the offspring of the non-exposed mothers. In relation to this, a higher odd of c-section (OR
11 1.55 (95% CI: 1.03, 2.31)) and a non-significantly higher odds of preterm birth (OR 1.74 (95%
12 CI: 0.93, 3.24)) were also associated with statin exposure in pregnancy. The associations
13 between statin use in pregnancy and low birth weight and preterm birth are supported by
14 similar findings in 469 statin exposed women in Taiwan ²², and a recent a real-world
15 pharmacovigilance study based on the Food and Drug Administration adverse effects
16 reporting system ²¹. On the contrary, a meta-analysis showed that statin use was associated
17 with reduced (although non-significantly) risk of preterm delivery ⁴¹. One previous study has
18 investigated adverse outcomes associations with statin use in women with FH: In 39
19 pregnancies, no adverse pregnancy outcomes was associated with statin use ⁶, although
20 statistical power is a limitation here. It has been suggested that the physiological state of FH
21 could impact the risk of premature births in relation to placental insufficiency ⁴², however as
22 we only observed excess risk among the statin-exposed pregnancies in women with FH (and

1 not in the total FH population) the underlying cause of this association should be further
2 investigated.

3 Unhealthy lifestyle behaviors such as smoking⁴³ in addition to high BMI and/or
4 excess weight gain during pregnancy, and babies born to mothers with diabetes are often
5 larger than expected for the gestational age, are all well known risk factors for low birth
6 weight⁴⁴. Except for slightly higher pre-pregnancy BMI among the statin-exposed
7 pregnancies, all other risk factors were similar in the statin-exposed and non-exposed group.
8 Still, we cannot rule out that there are other possible explanations for these associations.
9 Almost all women in our sample used statins due to their FH diagnosis, but since statins are
10 generally not recommended during pregnancy, those who continued statins during
11 pregnancy may differ in health behavior from their non-exposed counterparts.

12 **Strengths and limitations**

13 A major strength of the study is the use of MBRN registry data dated back to 1967 for all
14 pregnancies (from week 12-16 [depending on year of pregnancy]) in large cohorts of women
15 with and without FH residing in Norway. The MBRN contains a large amount of information
16 on pregnancy-related outcomes both in the mother and the offspring²⁵. We also obtained
17 data from the Norwegian patient registry on occurrence of coronary heart disease, stroke,
18 pulmonary embolism, deep vein thrombosis in association with pregnancy, however there
19 were too few cases to be included in the current study. Since statin use often is self-reported
20 and hence underestimated¹² and statin use during pregnancy in most cases probably is
21 unintentional, it is a major strength that we have objective data on pharmacy-dispensed
22 statins. Almost all adult women with a molecular genetic FH diagnosis are recommended to

1 use statins. Thus, use of statins due to other comorbidities like diabetes play a minor role.
2 However, we do not know for certain that the women took their statins as prescribed.

3 Since the registration period for variables in the MBRN varies (e.g. we only have
4 smoking information after 1999), we do not have complete datasets on all relevant exposure
5 measures. Similarly, there were too few cases of diabetes mellitus (all types) and chronic
6 hypertension prior to pregnancy to be able to adjust for this in the analysis. As we do not
7 have complete coverage of all comorbidities (including diabetes and hypertension diagnosis
8 from other sources than the MBRN), we cannot rule out that some of the associations
9 observed can be driven by pre-existing metabolic diseases. Since we do not have
10 information on all lifestyle habits, we cannot rule out residual confounding for our reported
11 associations. This may be particularly important for the associations between statin use and
12 adverse pregnancy outcomes.

13 To sum up, this longitudinal registry-based study demonstrates that women with
14 genetically verified FH have lower risk of gestational diabetes and intrapartum hemorrhage
15 during birth, but may have elevated risk of preeclampsia compared to controls, suggesting a
16 potential role of high LDL as a common risk factor. Reassuringly, no excess risk of adverse
17 pregnancy outcomes in offspring from mothers with FH were observed. However, statin use
18 in pregnancy among women with FH was associated with a higher risk of having offspring
19 with low birthweight. Although these results can be subject to confounding by lifestyle
20 factors, it may still support a continued precautionary approach towards statin use when
21 planning and during pregnancy. The higher frequency of preterm births among the statin
22 exposed pregnancies may be an explanation for the observed association that warrants
23 further investigation.

1

2 Acknowledgments

3 Data is obtained from several Norwegian health registries. However, the registries have
4 no role in the interpretation and presentation of data.

5

6 Funding

7 The study is funded by Helse Sør-Øst RHF (Norway), award number 2018095. PI: Kjetil
8 Retterstøl.

9 Disclosure of interest

10 KS, JJC, JI, HWK, LJM, DRJ, declare no conflict of interest. MPB has received honoraria for
11 lectures from Amgen, Sanofi, Novartis and Ultragenyx. KR has received personal
12 consultation honoraria from Norwegian Medicines Products Agency, and payment to Oslo
13 University Hospital from Thrombolysis in Myocardial Infarction (TIMI) Study Group and
14 honoraria for consultation to, in addition to honoraria for lectures from Amarin, Amgen,
15 Novartis and Sanofi. KBH has received honoraria from Sanofi and is a member of the
16 Scientific Advisory board of FH Europe Foundation.

17 Data availability statement

18 The anonymous data underlying this article may be obtained upon reasonable request to
19 the corresponding author.

REFERENCES

1. Hobbs HH, Brown MS and Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. *Hum Mutat.* 1992;1:445-66.
2. Humphries SE, Cooper JA, Capps N, Durrington PN, Jones B, McDowell IFW, Soran H and Neil AHW. Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register. *Atherosclerosis.* 2019;281:207-212.
3. Mundal L, Veierod MB, Halvorsen T, Holven KB, Ose L, Iversen PO, Tell GS, Leren TP and Retterstol K. Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study. *Eur J Prev Cardiol.* 2016;23:1962-1969.
4. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T, Swan L, Warnes CA and Group ESD. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). *European Heart Journal.* 2018;39:3165-3241.
5. Holven KB and Roeters van Lennep J. Sex differences in lipids: A life course approach. *Atherosclerosis.* 2023;384:117270.
6. Botha TC, Pilcher GJ, Wolmarans K, Blom DJ and Raal FJ. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. *Atherosclerosis.* 2018;277:502-507.
7. Mauri M, Calmarza P and Ibarretxe D. Dyslipemias and pregnancy, an update. *Clin Investig Arterioscler.* 2021;33:41-52.
8. Roes EM, Sieben R, Raijmakers MT, Peters WH and Steegers EA. Severe preeclampsia is associated with a positive family history of hypertension and hypercholesterolemia. *Hypertens Pregnancy.* 2005;24:259-71.
9. Spracklen CN, Smith CJ, Saftlas AF, Robinson JG and Ryckman KK. Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. *Am J Epidemiol.* 2014;180:346-58.
10. Cade WT, Mittendorfer B, Patterson BW, Haire-Joshu D, Cahill AG, Stein RI, Schechtman KB, Tinius RA, Brown K and Klein S. Effect of excessive gestational weight gain on insulin sensitivity and insulin kinetics in women with overweight/obesity. *Obesity.* 2022;30:2014-2022.
11. Hutcheon JA, Lisonkova S and Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. *Best Pract Res Clin Obstet Gynaecol.* 2011;25:391-403.
12. Toleikyte I, Retterstol K, Leren TP and Iversen PO. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. *Circulation.* 2011;124:1606-14.
13. Pieper PG. Use of medication for cardiovascular disease during pregnancy. *Nat Rev Cardiol.* 2015;12:718-29.
14. U.S Food and Drug Administration. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins. 2020.
15. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Aversa M, Boileau C, Boren J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Steinhagen-Thiessen E, Stroes ES, Taskinen MR, Tybjaerg-Hansen A and Wiklund O. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *Eur Heart J.* 2015;36:2425-37.
16. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L and Wiklund O. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J.* 2019.

17. Klevmoen M, Bogsrud MP, Retterstøl K, Svilaas T, Vesterbekkmo EK, Hovland A, Berge C, Roeters van Lennep J and Holven KB. Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia. *Atherosclerosis*. 2021;335:8-15.
18. Karalis DG, Hill AN, Clifton S and Wild RA. The risks of statin use in pregnancy: A systematic review. *J Clin Lipidol*. 2016;10:1081-90.
19. Benito-Vicente A, Uribe KB, Jebari S, Galicia-Garcia U, Ostolaza H and Martin C. Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. *Int J Mol Sci*. 2018;19.
20. Bateman BT, Hernandez-Diaz S, Fischer MA, Seely EW, Ecker JL, Franklin JM, Desai RJ, Allen-Coleman C, Mogun H, Avorn J and Huybrechts KF. Statins and congenital malformations: cohort study. *BMJ (Clinical research ed)*. 2015;350:h1035.
21. Wu T, Shi Y, Zhu B, Li D, Li Z, Zhao Z and Zhang Y. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). *Expert Opin Drug Saf*. 2024;23:313-321.
22. Chang JC, Chen YJ, Chen IC, Lin WS, Chen YM and Lin CH. Perinatal Outcomes After Statin Exposure During Pregnancy. *JAMA Netw Open*. 2021;4:e2141321.
23. Mundal L, Sarancic M, Ose L, Iversen PO, Borgan JK, Veierod MB, Leren TP and Retterstøl K. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010. *J Am Heart Assoc*. 2014;3:e001236.
24. Krogh HW, Svendsen K, Igland J, Mundal LJ, Holven KB, Bogsrud MP, Leren TP and Retterstøl K. Lower risk of smoking-related cancer in individuals with familial hypercholesterolemia compared with controls: a prospective matched cohort study. *Sci Rep*. 2019;9:19273.
25. Norwegian Institute of Public Health. Medical Birth Registry of Norway - purpose and responsibilities. 2023;2024.
26. Norwegian Institute of Public Health. The Norwegian Prescription database (in Norwegian).
27. Mulder JWCM, Kusters DM, Roeters van Lennep JE and Hutten BA. Lipid metabolism during pregnancy: consequences for mother and child. *Current Opinion in Lipidology*. 2024;1:35:133-140.
28. Steegers EA, von Dadelszen P, Duvekot JJ and Pijnenborg R. Pre-eclampsia. *Lancet*. 2010;376:631-44.
29. Bryan S. Quintanilla Rodriguez HM. Gestational Diabetes. 2023.
30. Svendsen K, Olsen T, Vinknes KJ, Mundal LJ, Holven KB, Bogsrud MP, Leren TP, Igland J and Retterstøl K. Risk of stroke in genetically verified familial hypercholesterolemia: A prospective matched cohort study. *Atherosclerosis*. 2022;358:34-40.
31. Norwegian Institute of Public Health. Medical Birth Registry- Statistical bank
32. Kjerpeseth LJ, Hjellvik V, Gulseth HL, Karlstad Ø, Lopez-Doriga Ruiz P, Wensaas KA and Furu K. Prevalence and treatment of gestational diabetes in Norway 2010-2020. *Diabetes Res Clin Pract*. 2024;207:111025.
33. Patek K and Friedman P. Postpartum Hemorrhage-Epidemiology, Risk Factors, and Causes. *Clin Obstet Gynecol*. 2023;66:344-356.
34. Langsted A, Kamstrup PR and Nordestgaard BG. High Lipoprotein(a) and Low Risk of Major Bleeding in Brain and Airways in the General Population: a Mendelian Randomization Study. *Clin Chem*. 2017;63:1714-1723.
35. Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ, Jr. and Simari RD. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. *Blood*. 2001;98:2980-7.
36. Nenseter MS, Lindvig HW, Ueland T, Langslet G, Ose L, Holven KB and Retterstøl K. Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia. *Atherosclerosis*. 2011;216:426-32.
37. Bogsrud MP, Graesdal A, Johansen D, Langslet G, Hovland A, Arnesen KE, Mundal LJ, Retterstøl K, Wium C and Holven KB. LDL-cholesterol goal achievement, cardiovascular disease, and

- 1 attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial
- 2 hypercholesterolemia. *J Clin Lipidol*. 2019.
- 3 38. Hovland A, Narverud I, Lie Øyri LK, Bogsrud MP, Aagnes I, Ueland T, Mulder M, Leijten F,
- 4 Langslet G, Wium C, Svilaas A, Arnesen KE, Roeters van Lennep J, Aukrust P, Halvorsen B, Retterstøl K
- 5 and Holven KB. Subjects with familial hypercholesterolemia have lower aortic valve area and higher
- 6 levels of inflammatory biomarkers. *J Clin Lipidol*. 2021;15:134-141.
- 7 39. Jacob EO, McIntyre AD, Wang J and Hegele RA. Lipoprotein(a) in Familial
- 8 Hypercholesterolemia. *CJC Open*. 2024;6:40-46.
- 9 40. Hedegaard BS, Nordestgaard BG, Kanstrup HL, Thomsen KK, Bech J, Bang LE, Henriksen FL,
- 10 Andersen LJ, Gohr T, Larsen LH, Soja AMB, Elpert FP, Jakobsen TJ, Sjørl A, Joensen AM, Klausen IC,
- 11 Schmidt EB and Bork CS. High lipoprotein(a) may explain one quarter of clinical familial
- 12 hypercholesterolemia diagnoses in Danish lipid clinics. *J Clin Endocrinol Metab*. 2023.
- 13 41. Vahedian-Azimi A, Bianconi V, Makvandi S, Banach M, Mohammadi SM, Pirro M and
- 14 Sahebkar A. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes.
- 15 *Atherosclerosis*. 2021;336:1-11.
- 16 42. KHOURY J, AMUNDSEN ÅL, TONSTAD S, HENRIKSEN T, OSE L, RETTERSTØL K and IVERSEN PO.
- 17 Evidence for impaired physiological decrease in the uteroplacental vascular resistance in pregnant
- 18 women with familial hypercholesterolemia. *Acta Obstetrica et Gynecologica Scandinavica*.
- 19 2009;88:222-226.
- 20 43. Arabzadeh H, Doosti-Irani A, Kamkari S, Farhadian M, Elyasi E and Mohammadi Y. The
- 21 maternal factors associated with infant low birth weight: an umbrella review. *BMC Pregnancy*
- 22 *Childbirth*. 2024;24:316.
- 23 44. K CA, Basel PL and Singh S. Low birth weight and its associated risk factors: Health facility-
- 24 based case-control study. *PLoS One*. 2020;15:e0234907.

25 Figure Legends

26

27 **Figure 1.** Flowchart of study inclusion of women with familial hypercholesterolemia (FH) and
28 age-matched controls.

29 **Figure 2.** Adverse pregnancy outcomes in women with familial hypercholesterolemia (FH)
30 versus controls. OR= odds ratio retrieved from logistic regression with clustered robust
31 standard error. Adjusted model= adjusted for mothers' age at pregnancy and children's birth
32 year in categories and parity. Large bleedings/ intrapartum hemorrhage = (>500 ml) during
33 delivery.

34 **Figure 3.** Adverse pregnancy outcomes in offspring from mothers with familial
35 hypercholesterolemia (FH) versus controls. OR= odds ratio retrieved from logistic regression
36 with clustered robust standard error. Adjusted model= adjusted for mothers age at

1 pregnancy and children's birth year in categories and parity. Preterm birth = Birth in
2 gestational week 37 or less. Any malformations = minor and major malformations
3 combined.

4 **Figure 4.** Number of prescriptions fills per 2-week period from one year before conception
5 to one year after birth in the FH population (n=1051). Conception is set to time zero, and the
6 bars are colored by prescription fill inside (red) or outside (blue) pregnancy, or those
7 prescription fill periods that overlap (carry-over) up to 42 days into pregnancy (green).

8 **Figure 5.** Risk of adverse pregnancy outcomes in pregnancies exposed to statins* (n=260)
9 versus pregnancies not exposed to statins (n=791) among women with FH. Odds ratio (OR)
10 retrieved from logistic regression, clustered robust standard error. Statin exposure: filling at
11 least one prescription for statins either during pregnancy, or before conception if the
12 prescription package duration would last into pregnancy. Adjusted model = adjusted for
13 mothers age at pregnancy and children's birth year in categories and parity. Large bleedings/
14 intrapartum hemorrhage = >500 ml during delivery. Preterm birth = birth in ≤gestational
15 week 37.

16
17